________________________________
Are you between 18-65?
Do you have moderate to Severe Eczema/Atopic Dermatitis for over a year?
Have you tried steroid or steroid-alternative creams on the skin in the past 6 months?
We accept participants of all sexes and also healthy participants.
You may be eligible for a study and receive up to $6375 for time and travel.
See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.
image credit: Freepik
image credit: FreepikBRIEF SUMMARY
This study aims to see if single doses of UCB1381 (intravenous and subcutaneous) are safe for healthy people. We’ll also test its safety when given multiple times to people with eczema. We’ll compare how effective it is when given multiple times to skin allergy patients against a placebo treatment.
CONDITIONS
Atopic Dermatitis
INTERVENTION / TREATMENT
Biological, Placebo
ENROLLMENT NATIONWIDE (ESTIMATED)
152
STUDY TYPE
Interventional
PHASE
Phase 1, Phase 2
AGES ELIGIBLE FOR STUDY
18 Years to 65 Years (Adult, Older Adult)
SEXES ELIGIBLE FOR STUDY
All
ACCEPTS HEALTHY VOLUNTEERS
Yes
Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05277571
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials here.
Page updated: August 2023
________________________________
Study Participation Details
About Trials and SWIA CRC
All our clinical research opportunities are FDA regulated and are sponsored by pharmaceutical companies or government agencies to develop new treatments or to study additional diseases for treatments currently approved for prescription. Each trial is conducted at many academic and private research centers that have been carefully chosen for their experience and reputation. SWIA Clinical Research Center, is a separate company affiliated with Midwest Allergy Sinus & Respiratory has operated over 1000 trials over the past 30 years and has been involved in developing many of the allergy and respiratory medicines you may be familiar with, including Zyrtec, Allegra, Singulair, Advair, Symbicort, Breztri, Trelegy, Nasonex, Xhance, Grastek, Ragwitek, Xolair, Dupixent, Palforzia, Stelara, Opzelura, Cibinqo, and Rinvoq, to name a few. Our highly trained clinical research staff follow strict protocols, which are in place to ensure safety, uniformity, and integrity. We have conducted studies with Volunteers from all walks of life, from infancy through advanced ages.
Contact us for more information, SWIA Clinical Research Dept.: Stephanie 309-451-7509 or Kady 309-452-0995 Ext 7522. You can also email us at research@asthma2.com, or fill out this contact this form.
